Gufic Biosciences Ltd vs Pfizer Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Gufic BioSciences Ltd is ₹ 293 as of 06 May 15:30 . The P/E Ratio of Gufic BioSciences Ltd is 33 as of March 2024 .The P/E Ratio of Pfizer Ltd is 0 as of March 2024 . The Market Cap of Gufic BioSciences Ltd is ₹ 2839 crore as of March 2024 .The Market Cap of Pfizer Ltd is ₹ 0 crore as of March 2024 . The revenue of Gufic BioSciences Ltd for the Dec '25 is ₹ 232.2 crore as compare to the Sep '25 revenue of ₹ 239.17 crore. This represent the decline of -2.91% The revenue of Pfizer Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Gufic BioSciences Ltd for the Dec '25 is ₹ 33.77 crore as compare to the Sep '25 ebitda of ₹ 39.96 crore. This represent the decline of -15.49% The ebitda of Pfizer Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Gufic BioSciences Ltd changed from ₹ 20.86 crore to ₹ 12.42 crore over 7 quarters. This represents a CAGR of -25.64% The net profit of Pfizer Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Gufic BioSciences Ltd changed from 2.19 % on March 2021 to 1.43 % on March 2025 . This represents a CAGR of -8.17% over 5 yearsThe Dividend Payout of Pfizer Ltd changed from 32.18 % on March 2021 to 98.34 % on March 2025 . This represents a CAGR of 25.03% over 5 years .

About Gufic BioSciences Ltd

Gufic Biosciences Limited is a prominent global pharmaceutical enterprise dedicated to delivering a broad spectrum of pharmaceutical services to its clients.
Renowned for its extensive range of pharmaceutical products, Gufic operates as a comprehensive solution provider in both domestic and international markets, supported by a robust distribution network.
The Company is ranked among the top 100 pharmaceutical companies in India. Gufic is a leading manufacturer of lyophilized injections in India, with a state-of-the-art automated lyophilization plant located in Navsari, Gujarat.
The Company was incorporated in July, 1984.
The recent addition of the Indore manufacturing facility has further solidified Gufic's position as one of the world's largest producers of lyophilized injections.

About Pfizer Ltd

Pfizer Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical products.
The Company offer a portfolio of 150 specialised medicines in 15 therapeutic areas across 4 business categories.
It has its own manufacturing facility at Goa and Thane.
It has the distinction of being the first pharmaceutical company in India to start clinical research.
The Company sells products in nearly 185 countries having 43 manufacturing sites globally.

FAQs for the comparison of Gufic BioSciences Ltd and Pfizer Ltd

Which company has a larger market capitalization, Gufic BioSciences Ltd or Pfizer Ltd?

Market cap of Gufic BioSciences Ltd is 2,938 Cr while Market cap of Pfizer Ltd is 21,875 Cr

What are the key factors driving the stock performance of Gufic BioSciences Ltd and Pfizer Ltd?

The stock performance of Gufic BioSciences Ltd and Pfizer Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gufic BioSciences Ltd and Pfizer Ltd?

As of May 6, 2026, the Gufic BioSciences Ltd stock price is INR ₹293.0. On the other hand, Pfizer Ltd stock price is INR ₹4781.85.

How do dividend payouts of Gufic BioSciences Ltd and Pfizer Ltd compare?

To compare the dividend payouts of Gufic BioSciences Ltd and Pfizer Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.